QCG
INO icon

Quadrant Capital Group’s Inovio Pharmaceuticals INO Stock Holding History

Quadrant Capital Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-693
Closed -$6.82K – 2730
2023
Q1 		$6.82K Sell
693
-384
-36% -$6.55K ﹤0.01% 2160
2022
Q4 		$20.2K Buy
1,077
+800
+289% +$18.1K ﹤0.01% 1653
2022
Q3 		$6K Buy
+277
New +$7.09K ﹤0.01% 2074
2021
Q4 		– Sell
-29
Closed -$2K – 2600
2021
Q3 		$2K Buy
29
+2
+7% +$201 ﹤0.01% 2154
2021
Q2 		$3K Buy
+27
New +$2.59K ﹤0.01% 2003
2021
Q1 		– Sell
-12
Closed -$1K – 2418
2020
Q4 		$1K Buy
+12
New +$1.6K ﹤0.01% 2131
2020
Q2 		– Sell
-6
Closed -$1K – 2302
2020
Q1 		$1K Buy
+6
New +$370 ﹤0.01% 1995

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Quadrant Capital Group's INO Position: Q2 2023 in Review

Quadrant Capital Group sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 693 shares — an estimated $6.82K sold.

Quadrant Capital Group first reported a position in INO in Q1 2020 and held it in 7 quarters. The position peaked at $20.2K in Q4 2022. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

  • Quadrant Capital Group reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 693 Inovio Pharmaceuticals shares in Q2 2023, an estimated $6.82K.
  • Quadrant Capital Group first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • Quadrant Capital Group's Inovio Pharmaceuticals position peaked at $20.2K in Q4 2022.
  • 133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.